Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Propensity score matching and multivariable Cox regression were used to compare overall survival (OS) and tumor-specific survival (TSS) between patients who underwent surgery and those who did not. The study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.
The study utilized de-identified data from the SEER program encompassing women aged ≥18 with histologically confirmed gastric-type endocervical adenocarcinoma between 2000 and 2021. The primary endpoints were overall survival and tumor-specific survival. Statistical analyses included multivariable Cox regression, propensity score matching (2:1), and inverse probability of treatment weighting (IPTW). Subgroup analyses were performed based on FIGO stage and tumor size (>4 cm). A total of 308 eligible cases were included. No patient interaction or clinical intervention occurred.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| surgical Resection Group | Participants in this group undergo standard surgical resection aimed at the complete or partial removal of tumor tissue. The type of surgery-open or minimally invasive-is determined based on the patient's clinical condition and the surgeon's judgment. Preoperative and/or postoperative adjuvant therapies, such as chemotherapy or radiotherapy, may be administered to enhance treatment efficacy. | ||
| Non-Surgical Management Group | Participants in this group receive standard non-surgical treatments, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. The specific treatment regimen is tailored to the patient's condition and determined by the treating physician, aiming to control tumor progression, alleviate symptoms, and improve quality of life. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Outcome | Overall Survival (OS) | Time from diagnosis to death from any cause Up to 22 years (2000-2022) |
Not provided
Not provided
Inclusion Criteria:
Histologically confirmed gastric-type endocervical adenocarcinoma Cervix as the first primary site Diagnosis between 2000 and 2021
Exclusion Criteria:
Incomplete survival or treatment data Diagnosis not confirmed microscopically
Not provided
Not provided
Not provided
This study enrolled patients aged 18 years and older with histologically confirmed gastric-type endocervical adenocarcinoma and no prior history of other malignancies.
Individual participant data (IPD) will not be shared due to concerns regarding participant privacy and confidentiality, as well as the absence of participant consent for data sharing.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided